Innovation Powers Us
Better Care Drives Us

Overview

Committed to Innovation
Dedicated to Improving Patient Lives

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.

NexoBrid® is our commercial orphan biologic drug for early non-surgical eschar removal of deep-partial and full-thickness thermal burns. It is a bromelain-based gel containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the United States, European Union, Japan, India, and other international markets. Its development is supported by the US Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS).

EscharEx® is MediWound’s leading biologic currently in development, utilizing the same active pharmaceutical ingredient found in NexoBrid. It is specifically designed for the debridement of chronic and hard-to-heal wounds. Promising results from Phase 2 studies demonstrate that EscharEx is highly effective and significantly faster than standard-of-care (SOC) treatments or placebo control in debriding venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). Furthermore, EscharEx exhibits a strong safety profile and excellent tolerability. The initiation of the Phase 3 study is anticipated in second half of 2024, marking a significant milestone in the development of EscharEx.

MW005 is an innovative topical biological drug currently in development to address the treatment needs of low-risk Basal Cell Carcinoma (BCC). In a Phase I/II open-label, multicenter, randomized clinical trial conducted in the U.S., MW005 was shown to be safe, well-tolerated, and an effective treatment for BCC with patients demonstrating complete clinical and histological clearance of target lesions.

 

Our Culture

Our People. Our Values. Our Culture

  • We care
  • We innovate
  • We deliver
  • We learn
At our company, we uphold the utmost ethical standards and prioritize the value of every individual. We genuinely care about our employees and believe in investing in their personal and professional development. We recognize that our people are our most valuable resources, and we are dedicated to fostering an environment where they can thrive.
At our company, we have a relentless drive for technological and scientific leadership. We are committed to pushing the boundaries and redefining the standard of care in the field of bio-therapeutics.

Through cutting-edge research and development, we strive to pioneer innovative solutions that address unmet medical needs. Our focus is on developing novel bio-therapeutic products that have the potential to revolutionize patient care and improve outcomes.

We invest heavily in scientific excellence and leverage the latest advancements in technology to stay at the forefront of our industry. Our dedicated team of researchers, scientists, and experts work tirelessly to uncover new insights, discover groundbreaking treatments, and bring them to fruition.
Customer satisfaction and improved patient outcomes are paramount to us. We prioritize our customers and are dedicated to delivering exceptional service. As a trusted partner, we strive to exceed expectations and provide reliable solutions that meet their specific needs.

We understand that our customers' success is intricately linked to the well-being and outcomes of patients. Therefore, we are committed to developing and delivering products and services that contribute to better patient experiences and improved health outcomes.
We embrace a culture of continuous learning and improvement as a fundamental aspect of our organization. We strive to be a learning organization that values the insights and experiences of those around us.

Individually, we recognize the importance of personal growth and development. We encourage our employees to cultivate a mindset of continuous learning, seeking new knowledge, skills, and perspectives that enable them to excel in their roles. We provide opportunities for professional development, training programs, and mentorship to support their ongoing learning journeys.

Collectively, as a company, we foster a collaborative environment where knowledge-sharing and teamwork thrive. We understand that innovation and progress are fueled by diverse perspectives and collective intelligence. We actively encourage open communication, collaboration, and the exchange of ideas within our organization.
"At MediWound, our exceptional team of dedicated professionals possesses the unique ability to turn visionary ideas into tangible realities. Our unwavering focus is to elevate the standard of care for our patients, ultimately enhancing their quality of life to a remarkable degree."

Ofer Gonen | Chief Executive Officer

"It fills me with immense joy and fulfillment to witness the realization of my vision: making NexoBrid accessible to patients globally, revolutionizing burn care for thousands of individuals worldwide. As a physician, the ability to leave such a profound mark in the field of medicine is the ultimate reward, reflecting the profound impact we can have on people's lives."

Professor Lior Rosenberg | Founder

The Total Solution

MediWound is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair.

Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care. MediWound is committed to providing rapid and effective biologics that improve patient experiences and outcomes while reducing costs and unnecessary surgeries.

RESEARCH & DEVELOPMENT

In-house Expertise

  • In-vitro and In-vivo models
  • Analytical methods
  • Product formulation
  • Clinical development and data generation
  • Regulatory processes

Research Collaborations with Solventum, Mölnlycke,
MIMEDX for EscharEx Phase 3 Trial

MANUFACTURING

Scale up of our new GMP-compliant, state-of-the-art manufacturing facility is on track to be completed by the end of June 2024. The facility will be fully operational in 2025, increasing our manufacturing capacity sixfold.

Current Manufacturing Facility

  • cGMP certified
  • Experienced team
  • Capable of aseptic processing for sterile products
  • Product Development manufacturing suites

Commercialization

Wide global network

  • Strategic collaborations: US (Vericel), Japan (Kaken), Europe (direct, and PMI), and India (BSV)
  • Supported by BARDA and DoD
  • Extensive worldwide supply chain

Our Team

Our People: Leading Change

  • Management
  • Board of Directors
  • Strategic Advisory Board

Ofer Gonen

Chief Executive Officer

Lior Rosenberg

Founder

Ety Klinger

Chief R&D Officer

Shmulik Hess

Chief Operating Officer & Chief Commercial Officer

Robert J. Snyder

Chief Medical Officer

Hani Luxenburg

Chief Financial Officer

Yaron Meyer

Executive Vice President & General Counsel

Barry Wolfenson

Executive Vice President of Strategy & Corporate Development

Andrey Kon

VP Plant Manager

Keren David-Zarbiv

VP Clinical Affairs

Eilon Asculai

VP Research & Development

Alicia Torrenova

VP European Operations

Aya Ben Yaakov

VP Regulatory Affairs

Alexandra (Sandra) Teplitsky

Executive Director of Quality Assurance

Professor Yaron Shoham

Medical Director

Asi Haviv

Medical Director

Nachum (Homi) Shamir

Chairman of the Board of Directors

Dr. Vickie R. Driver

Board Committee membership: R&D Committee (Chairperson), Audit Committee

David Fox

Board Committee membership: Nomination and Governance Committee (Chairperson), Compensation Committee

Shmuel (Milky) Rubinstein

Board Committee membership: Audit Committee, R&D Committee

Stephen T. Wills

Board Committee membership: Audit Committee (Chairperson), Compensation Committees, R&D Committee

Samuel Moed

Venture Partner at aMoon, Israel’s largest HealthTech VC fund

John C. Lantis

Chief of Surgery at Mount Sinai West Hospital in New York, practices as a senior vascular surgeon

Testimonials

Patients' Stories and Physicians' Experience

New York patient

treated with NexoBrid

Lee-Anne Jones

was treated witn NexoBrid

Prof. Dr. Jan Plock & Dr. Frank Sander

speak on their experince with NexoBrid